Is the success rate of Thailand's third-generation IVF high? A reproductive doctor analyzes from three dimensions: age, chromosomes, and laboratory
Author Identity
Thailand Third-Generation IVF Success Rate: Real Data by Age and Indication
The core of third-generation IVF technology (PGT, Preimplantation Genetic Testing) is to biopsy the blastocyst before transfer to screen for chromosomal number and structural abnormalities. Thailand commonly uses PGT-A (aneuploidy screening) and PGT-M (monogenic disease screening). Success rates are typically measured by the "live birth rate per single frozen embryo transfer," which is directly related to the embryo's chromosomal normality rate, which in turn is dominated by the woman's age.
| Female Age | Embryo Chromosomal Normality Rate (approx.) | Live Birth Rate per Single Transfer (approx.) | Cumulative Live Birth Rate (2-3 transfers) |
|---|---|---|---|
| ≤ 35 years | 60-70% | 50-65% | 75-85% |
| 36-37 years | 50-60% | 40-55% | 65-75% |
| 38-40 years | 35-45% | 25-40% | 45-60% |
| 41-42 years | 20-30% | 15-25% | 30-40% |
| ≥ 43 years | 10-15% | 5-10% | 10-20% |
The above data comes from annual reports of several mainstream Thai reproductive centers (such as Jetanin, BNH, Superior A.R.T., etc.) and data summaries from the ESHRE PGT Consortium. It is important to emphasize that these numbers are only achievable by centers with upper-level laboratory and doctor experience, and differences between centers can be as high as 10-20 percentage points.
Doctor's Perspective: The Real Value of Third-Generation IVF is Not in the "Success Rate Number"
As a reproductive doctor, when evaluating whether a technology is worth recommending, the core indicators are: clinical benefit and risk-benefit ratio.
The benefits of third-generation IVF are clear for the following groups:
- Recurrent spontaneous miscarriage (≥2 times): About 50-60% of early miscarriages are due to embryonic chromosomal abnormalities; PGT can significantly reduce the miscarriage rate.
- Advanced maternal age (≥38 years): The rate of embryonic chromosomal abnormalities increases exponentially with age; PGT can screen for chromosomally normal embryos for transfer.
- Carriers of chromosomal structural abnormalities: Such as balanced translocation, Robertsonian translocation; PGT-SR can screen for normal or balanced carrier embryos.
- Family history of monogenic diseases: PGT-M can prevent the transmission of genetic diseases to offspring.
However, for the following groups, third-generation IVF may not be the optimal choice:
- Young (<35 years), no history of miscarriage, normal chromosomes: The cumulative live birth rate with natural cycles or first/second-generation IVF is not significantly different from third-generation IVF, and the cost is lower and the cycle shorter.
- Severely diminished ovarian reserve (AMH <0.5 ng/mL, antral follicle count <3): Few eggs are retrieved, and the probability of forming a blastocyst for biopsy is low, potentially facing the risk of "no embryos available for transfer."
- Those solely wanting third-generation IVF to "improve success rates": It needs to be clear that third-generation IVF does not improve endometrial receptivity or embryo implantation ability; it only screens chromosomes.
In clinical decision-making, I tell patients: "Third-generation IVF is not magic; it is a screening tool. If your embryo pool contains chromosomally normal embryos, it helps you find them; if your embryo pool inherently has no normal embryos, it cannot create them." Therefore, the upper limit of the success rate is determined by your egg quality; third-generation IVF just helps you more precisely find that right embryo.
Age Stratification: Why 38 is a Key Turning Point
In the clinical pathway for third-generation IVF in Thailand, 38 years old is the starting age at which most centers recommend PGT. The reasons are:
| Age Group | Average Number of Eggs Retrieved | Blastocyst Formation Rate | Chromosomal Normality Rate | Clinical Recommendation |
|---|---|---|---|---|
| ≤ 35 years | 12-18 | 45-55% | 60-70% | PGT not mandatory unless history of miscarriage or chromosomal abnormality |
| 36-37 years | 8-14 | 40-50% | 50-60% | PGT can be considered, especially when egg count is sufficient |
| 38-40 years | 5-10 | 35-45% | 35-45% | Strongly recommend PGT, miscarriage risk significantly increased |
| 41-42 years | 3-7 | 25-35% | 20-30% | PGT essential, also prepare backup plan for egg donation |
| ≥ 43 years | 1-4 | 15-25% | 10-15% | PGT value limited, prioritize egg donation or embryo donation |
As seen in the table, after age 38, the embryonic chromosomal normality rate drops precipitously. This is why, for women over 40 undergoing third-generation IVF, although the live birth rate per single transfer is only 15-30%, if they transfer directly without PGT, the miscarriage rate could be as high as 40-50%. The value of third-generation IVF here is reflected as: exchanging the risk of "no embryo to transfer" for the certainty of "no miscarriage after transfer".
Thailand vs. Domestic vs. Western Countries: Structural Differences Behind Success Rates
Many patients ask: "Is the success rate of third-generation IVF in Thailand higher than in China?" This question needs to be broken down.
Laboratory Standards and Embryologist Experience
Top-ranked reproductive centers in Thailand (such as Jetanin, BNH, Superior A.R.T., iCare, etc.) are comparable to first-tier centers in China (such as Peking University Third Hospital, Shanghai Ninth People's Hospital, CITIC Xiangya, etc.) in key areas like blastocyst culture, embryo biopsy, and cryopreservation, with some centers even having a slight edge. Main reasons: Thai centers handle a large annual cycle volume, embryologists accumulate experience quickly, and laboratory quality control systems are mature.
Breadth of Indications
Thailand has more relaxed restrictions on indications for PGT compared to China. Chinese regulations stipulate that PGT is only applicable for clear medical indications like chromosomal abnormalities, monogenic diseases, and recurrent miscarriage; whereas in Thailand, some centers can perform PGT for recurrent implantation failure, advanced maternal age, and even social factors (such as sex selection). Broader indications mean a wider patient population, but it can also lower the overall success rate data because it includes many patients for whom PGT is not strictly necessary.
Cost and Value for Money
| Item | Thailand (Mainstream Centers) | China (First-tier Centers) | Western Countries (USA/UK) |
|---|---|---|---|
| Total cost per cycle (incl. medication, PGT) | 80,000 - 150,000 RMB | 60,000 - 120,000 RMB | 250,000 - 500,000 RMB |
| Blastocyst biopsy + PGT-A cost | 20,000 - 40,000 RMB | 15,000 - 30,000 RMB | 80,000 - 150,000 RMB |
| Frozen embryo transfer cycle | 20,000 - 40,000 RMB | 15,000 - 30,000 RMB | 80,000 - 120,000 RMB |
Thailand has a significant cost advantage over Western countries and is not far off from domestic costs. However, one must account for hidden costs like travel, accommodation, translation, and visas, which amount to about 20,000 - 40,000 RMB per cycle.
The Most Overlooked Difference: Laboratory Stability
Domestic reproductive centers are strictly regulated by the National Health Commission, with uniform laboratory quality control standards; Thai centers, however, vary in quality, with differences between laboratories potentially exceeding 20%. When choosing a Thai center, you should not just look at the "success rate" number. Pay attention to: the embryologist's annual biopsy volume, blastocyst freeze-thaw survival rate, and repeat validation data for PGT results.
Three Key Details Often Overlooked That Affect Success Rates
Detail 1: Biopsy Timing and Cell Number
PGT biopsy is usually performed on Day 5 or Day 6 blastocysts, with typically 3-5 cells biopsied. More biopsied cells mean more accurate results, but also a greater risk of damage to the embryo. An experienced embryologist can keep the impact of biopsy on blastocyst survival rate within 1-2% while ensuring diagnostic accuracy. If the blastocyst survival rate after biopsy is below 95%, the laboratory's technical level should be scrutinized.
Detail 2: Management of Mosaic Embryos
About 5-10% of blastocysts are mosaic, meaning some cells are chromosomally normal and some are abnormal. PGT results may report "low-level mosaic" or "high-level mosaic." Strategies for managing mosaic embryos vary greatly between centers: some discard them outright, while others recommend transfer with prenatal diagnosis. This directly affects the number of embryos ultimately available for transfer, thereby impacting the cumulative success rate.
Detail 3: Clinical Significance of Mitochondrial DNA Testing
Some Thai centers offer mitochondrial DNA copy number testing, claiming it can assess embryo viability. Current evidence-based medical evidence is insufficient, and the American Society for Reproductive Medicine (ASRM) explicitly recommends mitochondrial DNA testing for research purposes only. Using this test as a core criterion for embryo selection might actually eliminate potentially viable embryos, reducing the cumulative pregnancy rate.
Four Common but Costly Misconceptions
- Misconception 1: "Third-generation IVF success rate is over 90%" — Such promotional data usually refers to the "embryonic chromosomal normality rate" rather than the "live birth rate," and is not stratified by age. The actual live birth rate depends on age and diagnosis, as shown in the table above.
- Misconception 2: "Having third-generation IVF guarantees no miscarriage" — PGT screens for chromosomal number and structural abnormalities, but cannot detect single gene mutations (unless PGT-M is done), polygenic diseases, or miscarriages caused by non-chromosomal factors (such as intrauterine adhesions, immune abnormalities, endocrine issues). There is still a 5-10% risk of miscarriage after third-generation IVF.
- Misconception 3: "Third-generation IVF in Thailand allows sex selection and incidentally improves success rates" — Sex selection is legal in some Thai centers, but it does not change the embryo's chromosomal normality rate. Increasing the number of biopsy and transfer cycles for sex selection may actually reduce cumulative efficiency.
- Misconception 4: "Just choose the hospital with the highest success rate" — The "success rate" published by hospitals is often selected data (e.g., only counting people under 35 with normal ovarian function). You need to look at subgroup data matching your own conditions and request the "live birth rate per single transfer" rather than the "clinical pregnancy rate."
Six Core Tests to Assess Your Own Success Rate
| Test Item | Normal Range | Impact on Third-Generation IVF Success Rate |
|---|---|---|
| AMH (Anti-Müllerian Hormone) | ≥1.2 ng/mL | Predicts egg yield; lower AMH means fewer eggs retrieved and lower probability of forming a blastocyst for biopsy |
| FSH (Follicle-Stimulating Hormone) | ≤10 IU/L | Elevated FSH indicates diminished ovarian reserve, affecting response to ovarian stimulation |
| Antral Follicle Count (AFC) | ≥8 | Directly predicts the number of available follicles; efficiency of third-generation IVF drops significantly when AFC <5 |
| Chromosome Karyotype Analysis | 46,XX or 46,XY | Carriers of abnormalities (e.g., balanced translocation) must undergo PGT-SR, and success rates are lower than for non-carriers |
| Semen Analysis (DNA Fragmentation Index) | DFI ≤15% | Elevated fragmentation affects blastocyst formation rate and embryonic chromosomal stability |
| Hysteroscopy | Normal uterine cavity morphology | Lesions like endometrial polyps, adhesions, fibroids significantly reduce transfer success rates, even with normal embryos |
Before starting a third-generation IVF cycle in Thailand, it is recommended to complete all the above tests in your home country and bring the full reports for a remote consultation. This not only saves time but also avoids the risk of having to cancel the cycle temporarily in Thailand due to abnormal test results.
Frequently Asked Questions: 7 Practical Concerns from Patients
Step 1: Complete a full fertility assessment in your home country (AMH, FSH, AFC, chromosome karyotype, semen analysis, hysteroscopy) to determine your "success rate baseline."
Step 2: Conduct remote consultations with doctors from at least 2-3 Thai centers to get personalized plans and cycle estimates, rather than relying on the "overall success rate" from brochures.
Step 3: Develop a clear "decision tree"—under what conditions to continue, when to pause, and when to switch to egg donation or embryo donation. Do not start a high-cost cycle without a Plan B.
This article is compiled based on clinical consensus in reproductive medicine and publicly available data from 2025. It does not constitute medical advice. Individualized treatment plans must be developed after an in-person consultation with a licensed reproductive doctor.
